Recombinant Human ALKAL1 protein

ALKAL1 (ALK and LTK ligand 1), also known as augmentor-α, is a secreted protein belonging to the augmentor family, which includes ligands that interact with receptor tyrosine kinases ALK (anaplastic lymphoma kinase) and LTK (leukocyte tyrosine kinase). Discovered as a key regulator of cellular signaling, ALKAL1 plays a critical role in neural development, cell proliferation, and tissue homeostasis. Structurally, it contains conserved domains that facilitate binding to ALK/LTK receptors, activating downstream pathways such as RAS/MAPK and PI3K/AKT, which are pivotal for cell survival, differentiation, and oncogenesis. Dysregulation of ALKAL1-ALK signaling has been implicated in various cancers, including neuroblastoma and non-small cell lung cancer, highlighting its therapeutic relevance.

Recombinant ALKAL1 protein is engineered through genetic cloning and expression in heterologous systems (e.g., mammalian or bacterial cells) to produce a purified, bioactive form. This protein retains the functional epitopes necessary for receptor interaction, enabling researchers to study ALKAL1’s biological mechanisms, screen for inhibitors, or explore its role in disease models. Its production often includes tags (e.g., His-tag) for efficient purification and detection. Studies utilizing recombinant ALKAL1 have advanced understanding of ALK signaling dynamics, tumor microenvironments, and potential therapeutic targets. As a research tool, it supports drug discovery efforts aimed at modulating ALK-driven pathologies, underscoring its importance in both basic science and translational oncology.